The potential of brentuximab vedotin, alone or in combination with current clinical therapies, in the treatment of testicular germ cell tumors.
CD30 expression
Testicular germ cell tumor
brentuximab vedotin
chemotherapy
cisplatin
drug combination
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
02
2019
accepted:
25
03
2019
entrez:
21
6
2019
pubmed:
21
6
2019
medline:
21
6
2019
Statut:
epublish
Résumé
Testicular germ cell tumors (TGCTs) are the commonest tumors in young men. With the advancement of chemotherapies, most TGCTs are successfully cured, even when diagnosed at an advanced and metastatic stage. However, a proportion of often young patients, median age 35-40, with advanced disease are not cured and will inevitably die. Therefore, there is an unmet need in this small population of young patients who are candidates for experimental approaches. We investigated a new therapeutic option for this group of patients, aiming to significantly improve their outcome. In recent years, many targeted therapies have been developed which demonstrated high efficacy and low toxicity. Brentuximab vedotin, a monomethyl auristatin E conjugated CD30 antibody, targets CD30 to kill cancer cells. As a large proportion of TGCTs express CD30, in particular embryonal carcinomas, we investigated
Types de publication
Journal Article
Langues
eng
Pagination
855-871Déclaration de conflit d'intérêts
None.
Références
Acta Oncol. 2000;39(7):857-63
pubmed: 11145445
Histopathology. 2001 Oct;39(4):382-5
pubmed: 11683938
Genes Chromosomes Cancer. 2005 Jun;43(2):211-6
pubmed: 15761863
Proc Natl Acad Sci U S A. 2005 May 31;102(22):7946-51
pubmed: 15905329
Cancer. 2006 Mar 15;106(6):1217-26
pubmed: 16463389
Semin Diagn Pathol. 2005 Feb;22(1):33-50
pubmed: 16512598
Hum Pathol. 2006 Jun;37(6):662-7
pubmed: 16733205
Genes Chromosomes Cancer. 2008 Jul;47(7):604-13
pubmed: 18384131
Cancer Chemother Pharmacol. 2009 Oct;64(5):925-33
pubmed: 19263053
Clin Exp Dermatol. 2010 Jan;35(1):59-62
pubmed: 19486063
Ann Oncol. 2010 Apr;21(4):820-5
pubmed: 19822531
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Clin Cancer Res. 2010 Feb 1;16(3):888-97
pubmed: 20086002
Am J Pathol. 2010 Jun;176(6):2607-15
pubmed: 20395447
Cancer Res. 2010 Jul 1;70(13):5207-12
pubmed: 20516122
Int J Urol. 2010 Oct;17(10):881-5
pubmed: 20731738
Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):147-52
pubmed: 20881837
Mod Pathol. 2011 Jun;24(6):829-35
pubmed: 21780320
Clin Cancer Res. 2013 Jan 1;19(1):22-7
pubmed: 23155186
Am J Cancer Res. 2012;2(6):736-44
pubmed: 23226619
J Urol. 2013 Nov;190(5):1919-24
pubmed: 23624209
Int J Surg Pathol. 2013 Aug;21(4):342-51
pubmed: 23893437
J Pathol. 2014 Apr;232(5):566-77
pubmed: 24407904
Am J Surg Pathol. 2014 Jul;38(7):999-1006
pubmed: 24805861
Am J Hematol. 2015 Apr;90(4):E73
pubmed: 25546725
Blood. 2015 May 14;125(20):3118-27
pubmed: 25833963
Mol Cancer Ther. 2015 Jun;14(6):1376-84
pubmed: 25840583
Sci Transl Med. 2015 Jun 24;7(293):293ra102
pubmed: 26109102
Haematologica. 2016 Apr;101(4):e139-41
pubmed: 26703964
Cancer Res. 2016 May 1;76(9):2710-9
pubmed: 26921341
Clin Genitourin Cancer. 2016 Aug;14(4):261-264.e4
pubmed: 27105722
Oncotarget. 2016 Sep 27;7(39):63793-63803
pubmed: 27588475
Am J Cancer Res. 2016 Aug 01;6(8):1772-84
pubmed: 27648364
Sci Rep. 2017 Jul 11;7(1):5124
pubmed: 28698647
J Cell Mol Med. 2018 Jan;22(1):568-575
pubmed: 28941150
Case Rep Oncol. 2017 Sep 6;10(3):795-801
pubmed: 29158727
Oncologist. 2018 Mar;23(3):316-323
pubmed: 29222199
Lab Invest. 1997 Apr;76(4):497-504
pubmed: 9111512
APMIS. 1998 Jan;106(1):169-72; discussion 173
pubmed: 9524575
Anticancer Res. 1998 Jul-Aug;18(4C):3059-64
pubmed: 9713510